Adageis on Track to Exceed Q1 Growth Target, Expanding Healthcare AI Platform

• Adageis is surpassing its Q1 2025 growth targets, reflecting expanding market demand, with investment focused on team expansion, financial infrastructure, and AI development.
• Adageis’ patented AI-driven platform, already covering over 250,000 patient lives, optimizes quality healthcare for patients and revenue for healthcare providers.
• The company projects 580,000 patient lives covered by the end of Q2 2025.

Adageis, a healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations, is set to exceed its Q1 2025 growth expectations as its AI-powered platform continues to gain traction in the healthcare sector. The company now covers more than 250,000 patient lives, a sharp increase from its previously reported 150,000. This growth highlights a rising demand for technology that helps providers successfully transition from fee-for-service models to value-based care.

The company’s expansion is being driven by its ProActive Care Platform, an AI-powered system designed to streamline operations and improve revenue performance for healthcare providers. Currently utilized by 70 providers, the platform integrates with more than 90 electronic health record (“HER”) systems and has been awarded a U.S. patent for its predictive analytics capabilities.

Adageis plans to allocate its recent growth funding, as well as raised capital, toward three key areas: expanding its team to support the existing platform, upgrading financial infrastructure to launch into healthcare factoring, and enhancing its AI technology. The company expects to cover 580,000 patient lives by the end of Q2 2025, with monthly recurring revenue projected to reach $100,000. Additionally, Adageis is onboarding two to three new clients per month, further solidifying its unique position in the market.

Adageis is positioning itself as a key player in healthcare fintech, offering solutions that help providers optimize cash flow and maximize reimbursements. The company’s Patented Risk Engine (“PRE”) utilizes predictive analytics to assess revenue performance, enabling providers to forecast quality incentive payments. This capability allows healthcare organizations to factor accounts receivables and leverage debt for operational expansion.

The fintech AI solution is designed to address the complexities of insurance contracts, aggregating payments from insurance companies, accountable care organizations (“ACOs”), independent physician associations (“IPAs”), and clinically integrated networks (“CINs”). By providing these insights, Adageis enables healthcare professionals to secure funding based on expected reimbursements, reducing financial uncertainty.

A key factor in Adageis’ success is its ability to integrate seamlessly with widely used healthcare platforms, including AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic. This interoperability ensures that providers can implement the ProActive Care Platform without overhauling their existing systems, making it an attractive option for healthcare organizations looking to transition to value-based care.

The healthcare sector’s shift toward value-based care has created a demand for technology that can optimize revenue while improving patient outcomes. Adageis’ AI-powered platform is currently the only offering of its kind, providing an automated, scalable solution for healthcare providers navigating this transition.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN